This invention comprises oligodeoxynucleotides (ODNs) having at least 10 nucleotides with an unmethylated central CpG motif that are immunostimulatory in humans. The inventors have shown that the various ODNs of this invention (having different CpG notifs and backbones) induce immune responses from human non-B and B cells. The motif that stimulates non-B cells induces production and release of multiple T cell cytokines and chemokines; specifically, the Th1 cytokine IFN-gamma, which facilitates the development of a cytotoxic T cell response. In contrast, the motif that stimulates B cells induces production and release of various cytokines, including, but not limited to IL-6, which supports a Th2 antibody response. The inventors have generated in vitro and ex vivo data showing the ODNs of this invention have utility in precisely regulating the type and magnitude of the immune response in human cells. The present invention has multiple therapeutic uses, including but not limited to cancer, vaccine adjuvants, treating autoimmune disorders and immune system deficiencies, as well as an anti-infective agent and in combination with any antisense therapy.
U.S. Pat: No. 7,960,356 issued 2011-06-14
U.S. Pat: No. 6,977,245 issued 2005-12-20
U.S. Pat: No. 8,030,285 issued 2011-10-04
U.S. Pat: No. 8,389,495 issued 2013-03-05
U.S. Pat: No. 8,227,446 issued 2012-07-24
U.S. Pat: No. 8,741,869 issued 2014-03-06
PCT Application No. PCT/US2000/009839
Related international patent applications filed
Bill Ronnenberg, JD-MIP, MS
FDA Technology Transfer Program
10903 New Hampshire Ave.
Building WO1, Rm 4214
Silver Spring, MD 20993
OTT Reference No: E-1999-009
Updated: August 9, 2015